Drugs / CEL001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07259889 | Jun 2025 → Jun 2028 expected | — | Guangzhou Xiling Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEL001 | “The specification of CEL001 injection is:” NCT07259889 ↗ |
| Modality | Cell therapy | “NK cell preparation” NCT07259889 ↗ |
| Route | Intravenous | “administered intravenously” NCT07259889 ↗ |